Skip to content
HowShorted

Dianthus Therapeutics, Inc. short interest in 2021

In 2021, Dianthus Therapeutics, Inc.'s disclosed short interest ran from 3.85% of shares outstanding on 15 Jan 2021 to 2.00% on 31 Dec 2021, a change of -1.85 percentage points. The year's high was 4.22% on 15 Apr 2021 and its low 2.00% on 31 Dec 2021, averaging 3.10% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 18.16 days on 30 Apr 2021. Full history: Dianthus Therapeutics, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2019 · 2020 · 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for Dianthus Therapeutics, Inc. in 2021

2021 in figures

Start of year
3.85% (15 Jan 2021)
End of year
2.00% (31 Dec 2021)
Change
-1.85 pp
High
4.22% (15 Apr 2021)
Low
2.00% (31 Dec 2021)
Average
3.10%
Highest days to cover
18.16 (30 Apr 2021)
SEC filings marked
10

Every report in 2021

Dianthus Therapeutics, Inc. short interest in 2021
SettlementShort interestDays to coverFilings since previous
15 Jan 20213.85%7.98results (8-K)
29 Jan 20213.52%7.88
12 Feb 20213.45%5.61
26 Feb 20213.56%3.88
15 Mar 20213.98%4.5510-K filed, results (8-K)
31 Mar 20214.11%13.60
15 Apr 20214.22%11.68
30 Apr 20214.03%18.16
14 May 20213.83%9.1410-Q filed, results (8-K)
28 May 20213.52%7.93
15 Jun 20213.26%10.94
30 Jun 20213.31%4.46
15 Jul 20213.37%11.68
30 Jul 20213.39%5.97results (8-K)
13 Aug 20212.76%6.0210-Q filed, results (8-K)
31 Aug 20212.25%6.11
15 Sep 20212.18%5.70
30 Sep 20212.60%4.83
15 Oct 20212.40%10.39
29 Oct 20212.32%12.40
15 Nov 20212.18%7.7610-Q filed, results (8-K)
30 Nov 20212.29%7.15
15 Dec 20212.06%6.18
31 Dec 20212.00%5.50

See also: Dianthus Therapeutics, Inc.'s full history · most shorted US stocks of 2021 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.